RIGL Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Revenue & Profitability TurnaroundA multi-year reversal to sharply higher revenue and sustained operating/net margins transforms Rigel from a loss-making biotech to a commercial cash generator. Durable commercial traction supports recurring revenue, funds R&D and business development, and reduces financing reliance over the next 2–6 months and beyond.
Commercial Portfolio MomentumBroad-based product growth across two lead products, plus a stable GAVRETO franchise, implies diversified revenue streams and less single-product risk. Consistent adoption trends across academic and community settings strengthen market positioning and support predictable medium-term revenue evolution.
Improved Cash Flow & Balance SheetPositive operating and free cash flow with a strengthened balance sheet and low relative leverage improve financial flexibility. Repayment of a term loan and a revolver provide liquidity optionality for launches, BD investments, or milestone payments without immediate equity issuance.
Bears Say
Earnings Volatility & Quality RiskRapid swings from losses to outsized profits indicate earnings may be driven by timing or non‑cash items, undermining persistence. For investors this raises caution about forecasting future margins and cash conversion, and complexity in relying on short run profitability as durable.
Rising Operating Costs / Margin PressureHigher R&D and commercial expenses to support pipeline and launches can erode the recent profit inflection. If revenue growth slows or costs accelerate further, free cash flow and margins could compress, limiting the sustainability of current profitability over the medium term.
Program & BD Execution RiskLoss of an external collaborator forces Rigel to absorb development choice and costs or re‑partner assets, increasing execution risk. Concurrent BD moves (e.g., VEPPANU rights with $70M upfront) raise obligations; combined effects heighten execution and funding demands across programs.
Rigel News
RIGL FAQ
What was Rigel Pharmaceuticals’s price range in the past 12 months?
Currently, no data Available
What is Rigel Pharmaceuticals’s market cap?
Currently, no data Available
When is Rigel Pharmaceuticals’s upcoming earnings report date?
Rigel Pharmaceuticals’s upcoming earnings report date is Aug 04, 2026 which is in 8 days.
How were Rigel Pharmaceuticals’s earnings last quarter?
Rigel Pharmaceuticals released its earnings results on May 05, 2026. The company reported $0.358 earnings per share for the quarter, missing the consensus estimate of $0.647 by -$0.289.
Is Rigel Pharmaceuticals overvalued?
According to Wall Street analysts Rigel Pharmaceuticals’s price is currently Undervalued.
Does Rigel Pharmaceuticals pay dividends?
Rigel Pharmaceuticals does not currently pay dividends.
What is Rigel Pharmaceuticals’s EPS estimate?
Rigel Pharmaceuticals’s EPS estimate is 0.07.
How many shares outstanding does Rigel Pharmaceuticals have?
Currently, no data Available
What happened to Rigel Pharmaceuticals’s price movement after its last earnings report?
Rigel Pharmaceuticals reported an EPS of $0.358 in its last earnings report, missing expectations of $0.647. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Rigel Pharmaceuticals?
Currently, no hedge funds are holding shares in CH:RIGL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rigel Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
79.83%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
186.75%
Trailing 12-Months
Company Description
Rigel Pharmaceuticals
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
RIGL Company Deck
RIGL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys a generally positive commercial and strategic outlook: strong top-line product growth (26% YoY overall; 31% YoY for TAVALISSE and REZLIDHIA), clear 2026 guidance and a pathway to full-year profitability, alongside promising early clinical data for R289 and expanded international partner revenues. Offsetting risks include rising operating expenses, a modest decline in quarterly net income and cash, seasonal Q1 reimbursement headwinds, a slower-growing GAVRETO franchise, and the termination of the Lilly collaboration for the RIPK1 asset (creating program-level uncertainty). On balance, the highlights—robust product sales growth, maintained guidance, pipeline progress and improved financing flexibility—outweigh the lowlights.View all CH:RIGL earnings summariesRIGL Stock 12 Month Forecast
Average Price Target
$48.45